OREANDA-NEWS. Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has been selected to present at the Biotech Showcase 2016, San Francisco, on:

Monday, January 11, 2016 at 1400 PST

Track: D - Powell (3rd Floor)

Biotech Showcase, which runs alongside the largest healthcare investor event of the year - the JP Morgan Annual Healthcare Conference - is an investor and partnering conference dedicated to providing private and public life sciences companies an opportunity to meet with investors and pharmaceutical executives from around the world.

Graham Lumsden, Chief Executive Officer at Motif, said: "Being selected to present at such an important event is recognition of Motif's success to date and future potential. Members of the Motif Leadership Team will be in San Francisco to meet pharma and biotech investors and partners attending the Biotech Showcase and JP Morgan conference."

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus).  Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.